_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The platform’s technology works as a compression algorithm for molecular testing
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
An MoU was signed between B Medical Systems and Gujarat government recently
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
Sputnik M is a new member of the Sputnik vaccines family
Subscribe To Our Newsletter & Stay Updated
